Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel [5]

Clinical and Experimental Dermatology

Volumn 30, Issue 6, 2005, Pages 712-713

  Dawe, S A ^a   Salisbury, J R ^a   Higgins, E ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; HYALURONIC ACID;

AGED; ANTIINFLAMMATORY ACTIVITY; BOWEN DISEASE; CASE REPORT; DERMATITIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY SKIN; GEL; HUMAN; HUMAN TISSUE; LETTER; MALE; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN IRRITATION; SQUAMOUS CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BOWEN'S DISEASE; DICLOFENAC; DRUG COMBINATIONS; GELS; HUMANS; HYALURONIC ACID; MALE; TREATMENT OUTCOME;

EID: 27144452276     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2005.01867.x     Document Type: Letter

References (5)

1. Chute CG, Chuang TY, Bergstralh EJ et al. The subsequent risk of internal cancer with Bowen's disease. A population-based study. JAMA 1991; 266: 816-19.
2. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-42.
3. Freemantle C, Alam CA, Brown JR et al. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Int J Tissue React 1995; 17: 157-66.
4. Seed MP, Brown JR, Freemantle CN et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997; 57: 1625-9.
5. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. Int J Tissue React 1995; 17: 153-6.